Atisha-Fregoso Yemil, Espejo-Poox Eric, Carrillo-Maravilla Eduardo, Pulido-Ramírez Alma Lilia, Lugo Baruqui Diego, Hernández-Molina Gabriela, Cabral Antonio R
Medicine Division, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Av. Vasco de Quiroga 15. Col. Belisario Domínguez, Sección XVI, Tlalpan, Mexico City, 14080, DF, Mexico.
Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Av. Vasco de Quiroga 15. Col. Belisario Domínguez, Sección XVI, Tlalpan, 14080, México, D.F., Mexico.
Rheumatol Int. 2017 Jul;37(7):1159-1164. doi: 10.1007/s00296-017-3727-0. Epub 2017 May 4.
The objective was to describe the management and risk factors for complications of antiphospholipid syndrome (APS) patients who underwent a surgical procedure in a single center. We reviewed medical records of all patients with primary or secondary APS who underwent an elective surgery during a 6-year period. Demographical data, management of anticoagulation and complications were recorded. We identified 43 patients, mean age 37.9 ± 8.9 years, who underwent a total of 48 elective surgeries. All patients had history of at least one thrombotic event and were under vitamin K antagonists. Before surgery, all patients received bridging therapy with intravenous infusion of heparin or low molecular weight heparin (LMWH). Among the LMWH group, 36 had a full anticoagulation regimen and nine prophylactic doses. In 62% of the surgeries, we identified an optimal management of periprocedural anticoagulation according to guidelines. Overall six patients had severe bleeding and three thrombotic complications (full anticoagulation regimen n = 2 and prophylactic dose group n = 1). Patients with optimal management of anticoagulation experienced less thrombotic and hemorrhagic complications (7 vs. 33%; OR 0.14, 95% CI 0.02-0.81; p = 0.040) and patients with INR ≤1.5 at surgery had fewer episodes of major bleeding (6 vs. 29%; OR 0.19, 95% CI 0.02-0.98; p = 0.050). All three thrombotic events occurred in patients with INR ≤1.5. Proper management of anticoagulation based on guidelines is associated with less complications in patients with APS. Notwithstanding the proper use of bridging therapy, some patients may develop thrombotic complications.
目的是描述在单一中心接受外科手术的抗磷脂综合征(APS)患者并发症的管理及风险因素。我们回顾了在6年期间接受择期手术的所有原发性或继发性APS患者的病历。记录人口统计学数据、抗凝管理及并发症情况。我们确定了43例患者,平均年龄37.9±8.9岁,共接受了48例择期手术。所有患者均有至少一次血栓形成事件史,且正在接受维生素K拮抗剂治疗。手术前,所有患者均接受静脉输注肝素或低分子量肝素(LMWH)的桥接治疗。在LMWH组中,36例采用全抗凝方案,9例采用预防剂量。在62%的手术中,我们根据指南确定了围手术期抗凝的最佳管理。总体而言,6例患者发生严重出血,3例发生血栓形成并发症(全抗凝方案组n = 2,预防剂量组n = 1)。抗凝管理最佳的患者发生血栓形成和出血并发症的情况较少(7%对33%;OR 0.14,95%CI 0.02 - 0.81;p = 0.040),手术时国际标准化比值(INR)≤1.5的患者大出血发作较少(6%对29%;OR 0.19,95%CI 0.02 - 0.98;p = 0.050)。所有3例血栓形成事件均发生在INR≤1.5的患者中。基于指南对抗凝进行适当管理与APS患者较少的并发症相关。尽管正确使用了桥接治疗,但一些患者仍可能发生血栓形成并发症。